Table 2 Comparisons between the groups at week 12: adjusted values from ANCOVA analysis
From: Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD
BDP/FF | FP/S | Between groups p value | |
|---|---|---|---|
(N = 211) | (N = 207) | ||
Pre-dose morning FEV1, litre | 0.08 (0.04 to 0.11) | 0.06 (0.03 to 0.10) | 0.58 |
Pre-dose morning FVC, litre | 0.06 (-0.00 to 0.13) | 0.05 (-0.01 to 0.12) | 0.82 |
SGRQ score | -5.92 (-7.75 to -4.08) | -3.80 (-5.70 to -1.90) | 0.08 |
SGRQ decrease from baseline > 4, patients (%) | 95 (45.0) | 75 (36.2) | 0.16 |
6MWTa, meters | 31.62 (15.18 to 48.06) | 22.23 (6.30 to 38.16) | 0.33 |
6MWT changea > 37 meters, patients (%) | 39 (18.8) | 34 (16.4) | 0.60 |
Symptom scoreb | -1.21 (-1.55 to -0.87) | -1.00 (-1.35 to -0.65) | 0.36 |
Breathlessness on risingb | -0.26 (-0.35 to -0.18) | -0.24 (-0.32 to -0.16) | 0.65 |
Symptom-free daysc,% | 4.60 (1.79 to 7.41) | 5.88 (2.99 to 8.76) | 0.50 |
Use of rescue medicationb, puffs | -0.60 (-0.78 to -0.42) | -0.63 (-0.81 to -0.45) | 0.80 |
Rescue medication-free daysc,% | 13.50 (9.39 to 17.61) | 13.11 (8.89 to 17.32) | 0.89 |